Conv. Plasma
Nigella Sativa
Peg.. Lambda

All remdesivir studies
Meta analysis
Home COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  

Remdesivir for the treatment of COVID-19

Anseems et al., Cochrane Database of Systematic Reviews, doi:10.1002/14651858.CD014962
Aug 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Review of 5 RCTs prior to April 17, 2021 showing mortality RR 0.93 [0.81-1.06] for hospitalized patients.
Currently there are 60 remdesivir studies and meta analysis shows:
Mortality11% lower [3‑18%]
Ventilation10% higher [-22‑54%]
ICU admission33% higher [10‑62%]
Hospitalization5% higher [-17‑33%]
Anseems et al., 5 Aug 2021, preprint, 10 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperRemdesivirAll
Remdesivir for the treatment of COVID-19
Kelly Ansems, Felicitas Grundeis, Karolina Dahms, Agata Mikolajewska, Volker Thieme, Vanessa Piechotta, Maria-Inti Metzendorf, Miriam Stegemann, Carina Benstoem, Falk Fichtner
Cochrane Database of Systematic Reviews, doi:10.1002/14651858.cd014962
Trusted evidence. Informed decisions. Better health.
Cochrane Library Trusted evidence. Informed decisions. Better health. Cochrane Database of Systematic Reviews Did patients get better with remdesivir? • Remdesivir may have little or no e ect on the length of time patients spent on invasive mechanical ventilation (2 studies, 1298 people). • We do not know whether remdesivir increases or decreases time on supplemental oxygen (3 studies, 1691 people). Did patients get worse with remdesivir? • We do not know whether patients are more or less likely to need any mechanical ventilation (invasive or non-invasive) with remdesivir (3 studies, 6696 people). • Patients may be less likely to need invasive mechanical ventilation (2 studies, 1159 people). • We do not know whether patients are more or less likely to need non-invasive mechanical ventilation (1 study, 573 people). • We do not know whether patients are more or less likely to need oxygen by mask or nasal prongs (1 study, 138 people) . Quality of life • None of the included studies reported quality of life. Unwanted e ects • We do not know whether remdesivir leads to more or fewer unwanted e ects of any level (3 studies, 1674 people) . • Patients are probably less likely to experience serious unwanted e ects with remdesivir than with placebo or standard care (3 studies, 1674 people) . In 1000 people, 63 fewer would experience a serious unwanted e ect compared to placebo or standard care. What are the limitations of the evidence? We are moderately confident in the..
Ader ; Ader, Er-Smadja, Poissy, Bouscambert-Duchamp, Belhadi et al., Antiviral drugs in hospitalised patients with COVID-19 -the DisCoVeRy trial, CLINICALTRIALS.GOV, doi:10.1101/2021.01.08.20248149
Beigel, Beigel, Tomashek, Dodd, Mehta et al., Remdesivir for the treatment of COVID-19 -final report, New England Journal of Medicine, doi:10.1056/NEJMoa2007764
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of COVID-19 -preliminary report, New England Journal of Medicine, doi:10.1056/NEJMoa2007764
Beigel, Tomashek, Dodd, Remdesivir for the treatment of COVID-19 -preliminary report, New England Journal of Medicine, doi:10.1056/NEJMc2022236
Deresinski, Treatment of COVID-19 patients with remdesivir, hydroxychloroquine, lopinavir, or interferon beta-1a
Elliott, Elliot, Chan, Deresinski 2020 {published data only} Deresinski S. Remdesivir and COVID-19
Epstein, Avoiding the termination of ACTT, doi:10.1093/eurheartj/ehaa546]EUCTR2020-001052-18-
Excel, Microso Corporation ; Moher ; Moher, Liberati, Tetzla, Altman et al., SARS-coronavirus-2 replication in Vero E6 cells: replication kinetics, rapid adaptation and cytopathology, New England Journal of Medicine, doi:10.1371/journal.pmed.1000097
Eynde, Consortium. Repurposed antiviral drugs for COVID-19 -interim WHO solidarity trial results, New England Journal of Medicine, doi:10.3390/ph13050098
Funk, Pharris, Spiteri, Bundle, Melidou et al., Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021, Eurosurveillance, doi:10.2807/1560-7917.ES.2021.26.16.2100348
Galiuto, Patrono, Conflicting results on the e icacy of remdesivir in hospitalised COVID-19 patients: comment on the adaptive COVID-19 treatment trial, doi:10.1093/eurheartj/ehaa934]ISRCTN13035264
Gautret, Million, Jarrot, Jau, Colson et al., Natural history of COVID-19 and therapeutic options, Expert Review of Clinical Immunology, doi:10.1080/1744666X.2021.1847640
Goldberg, Zvi, Sheena, Sofer, Krause et al., A real-life setting evaluation of the e ect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel, doi:10.1056/NEJMoa2015301]ISRCTN15874265
Goldman, Goldman, Lye, Hui, Marks et al., Impact of baseline alanine aminotransferase levels on the safety and e icacy of remdesivir in severe COVID-19 patients
Grubaugh, Hanage, Rasmussen, Higgins, Thompson et al., Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear, doi:10.1016/j.cell.2020.06.040
Harrington, Baden, Hogan, A large, simple trial leading to complex questions, New England Journal of Medicine, doi:10.1056/NEJMe2034294]ISRCTN83971151
Hsu, Lai, Yen, Chen, Chen, E icacy of remdesivir in COVID-19 patients with a simulated twoarm controlled study, doi:10.1101/2020.05.02.20088559
Hu 2020 Hu, Song, Xu, Chen, Xu, Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China, Science China Life Sciences, doi:10.1007/s11427-020-1661-4
Huang 2020 Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Kaka 2021 Kaka, Macdonnald, Greer, Vela, Duan-Porter et al., Major update: remdesivir for adults with COVID-19: a living systematic review and meta-analysis for the American College of Physicians Practice Points, Annals of Internal Medicine, doi:10.7326/L21-0130
Karagiannidis, Mostert, Hentschker, Voshaar, Malzahn et al., Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study, Cochrane Database of Systematic Reviews, doi:10.1016/S2213-2600(20)30316-7
Ko, Remdesivir reduces time to recovery in adults hospitalised with COVID-19: a meaningful step in therapeutic discovery, Journal of Clinical Outcomes Management, doi:10.1056/NEJMoa2007764]NCT04280705
Kupferschmidt, WHO's treatment megatrial is at a standstill, doi:10.1126/science.371.6533.972
Lai 2021 Lai, Chen, Wang, Chen, Wang et al., Clinical e icacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomised controlled trials, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkab093
Li 2020b Li, Geng, Peng, Meng, Lu et al., Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Journal of Pharmaceutical Analysis, doi:10.1016/j.jpha.2020.03.001
Lo 2017 Lo, Jordan, Arvey, Sudhamsu, Shrivastava-Ranjan et al., GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses, Scientific Reports, doi:10.1038/srep43395
Malaiyan, Arumugam, Mohan, Malin ; Malin, Suárez et al., An update on the origin of SARS-CoV-2: despite closest identity, bat (RaTG13) and pangolin derived coronaviruses varied in the critical binding site and O-linked glycan residues, Clinical Microbiology Reviews, doi:10.1002/jmv.26261
Mcguigan, Hassan-Abdallah, Srinivasan, Wang, Siddiqui et al., Application of phosphoramidate ProTide technology significantly improves antiviral potency of carbocyclic adenosine derivatives, Journal of Medicinal Chemistry, doi:10.1021/jm060776w
Meng ; Meng, Xiong, He, Lin, Hao et al., CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China, Journal of Infection, doi:10.1016/j.jinf.2020.04.004
O N T R I B U T I O N S O F A U T H O R S Ka ; D E C L A R A T I O N S O F I N T E R, CB: methodological expertise and advice, data extraction and assessment, conception, writing and proofreading of the manuscript. FF: clinical expertise and advice, data extraction and assessment, conception, writing and proofreading of the manuscript
Olalla, Remdesivir for the treatment of COVID-19 -preliminary report, New England Journal of Medicine, doi:10.1056/NEJMc2022236
Olsen, Henriksen, Kåsine, Lund-Johansen, Hoel, Evaluation of remdesivir and hydroxychloroquine on viral clearance in COVID-19 patients: results from the NOR-solidarity randomised trial, CLINICALTRIALS.GOV, doi:10.2139/ssrn.3774182
Oran ; Oran, Topol, Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review, Annals of Internal Medicine, doi:10.7326/M20-3012
Paladugu, Donato, Remdesivir improved time to recovery in adults hospitalised with COVID-19 and lower respiratory tract involvement, Annals of Internal Medicine, doi:10.7326/ACPJ202007210-005
Pan 2020 Pan, Liu, Wang, Guo, Hao et al., Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study, Statistics in Medicine, doi:10.1001/jama.2020.6130
Pan, Peto, Karim, Alejandria, Henao-Restrepo et al., Repurposed antiviral drugs for COVID-19 -interim WHO solidarity trial results, CLINICALTRIALS.GOV, doi:10.1101/2020.10.15.20209817
Piechotta, Valk, Chai, Wood, Lamikanra et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, doi:10.1371/journal.pone.0243705
Schilling, Lehfeld, Schumacher, Ullrich, Diercke et al., Disease severity of the first COVID-19 wave in Germany using reporting data from the national notification system, doi:10.25646/7170
Schwarz, Tober-Lau, Hillus, Helbig, Lippert et al., Comparative therapeutic e icacy of remdesivir and combination lopinavir, ritonavir and interferon beta against MERS-CoV, Science Translational Medicine, doi:10.3201/eid2708.211145
Siegel 2017 Siegel, Hui, Doer Ler, Chun, Zhang, Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the treatment of ebola and emerging viruses, Cochrane Database of Systematic Reviews, doi:10.1021/acs
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop